How can we prevent multisystem complications of cystic fibrosis?

被引:13
作者
Elborn, J. Stuart
机构
[1] QUB, Resp Med Grp, Belfast, Antrim, North Ireland
[2] BCH, No Ireland Adult Cyst Fibrosis Ctr, Belfast, Antrim, North Ireland
关键词
cystic fibrosis; inflammation; osteoporosis; diabetes; liver disease;
D O I
10.1055/s-2007-981651
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Cystic fibrosis (CF) is a multisystem disease. Some of this is accounted for by CF transmembrane regulator (CFTR) dysfunction in individual organs but in some cases this is compounded by the effects of systemic inflammation. The inflammation is in response to the chronic infection in the airways and is particularly important as a contributor to CF-related bone disease, CF-related diabetes mellitus, CF-related arthropathy, and vasculitis. Preventing these multisystem complications is difficult. Aggressive specific therapies to treat complications is critically important to maintain nutrition, stop the damaging effects of diabetes, and improve bone mineral density. Aggressive treatment of lung disease to reduce systemic inflammation is likely to be of benefit in preventing the development of CF-related bone disease and may be beneficial in at least delaying the onset of CF-related diabetes. Aggressive treatment of pulmonary infection and inflammation in conjunction with holistic management plans to treat specific organ diseases is an important strategy in improving morbidity and reducing mortality in people with CF.
引用
收藏
页码:303 / 311
页数:9
相关论文
共 84 条
[51]   Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition [J].
Hardin, DS ;
Rice, J ;
Ahn, C ;
Ferkol, T ;
Howenstine, M ;
Spears, S ;
Prestidge, C ;
Seilheimer, DK ;
Shepherd, R .
JOURNAL OF PEDIATRICS, 2005, 146 (03) :324-328
[52]   Normal bone mineral density in cystic fibrosis [J].
Hardin, DS ;
Arumugam, R ;
Seilheimer, DK ;
LeBlanc, A ;
Ellis, KJ .
ARCHIVES OF DISEASE IN CHILDHOOD, 2001, 84 (04) :363-368
[53]   Mechanisms of insulin resistance in cystic fibrosis [J].
Hardin, DS ;
Leblanc, A ;
Marshall, G ;
Seilheimer, DK .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2001, 281 (05) :E1022-E1028
[54]   Low bone mineral density in adults with cystic fibrosis [J].
Haworth, CS ;
Selby, PL ;
Webb, AK ;
Dodd, ME ;
Musson, H ;
Niven, RM ;
Economou, G ;
Horrocks, AW ;
Freemont, AJ ;
Mawer, EB ;
Adams, JE .
THORAX, 1999, 54 (11) :961-967
[55]   Inflammatory related changes in bone mineral content in adults with cystic fibrosis [J].
Haworth, CS ;
Selby, PL ;
Webb, AK ;
Martin, L ;
Elborn, JS ;
Sharples, LD ;
Adams, JE .
THORAX, 2004, 59 (07) :613-617
[56]   Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis [J].
Haworth, CS ;
Selby, PL ;
Adams, JE ;
Mawer, EB ;
Horrocks, AW ;
Webb, AK .
THORAX, 2001, 56 (04) :314-316
[57]   Bone density, body composition, and inflammatory status in cystic fibrosis [J].
Ionescu, AA ;
Nixon, LS ;
Evans, WD ;
Stone, MD ;
Lewis-Jenkins, V ;
Chatham, K ;
Shale, DJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (03) :789-794
[58]  
JALAN R, 2000, GUT, V46, pS3
[59]   Reduced bone density in cystic fibrosis:: ΔF508 mutation is an independent risk factor [J].
King, SJ ;
Tolpliss, DJ ;
Kotsimbos, T ;
Nyulasi, IB ;
Bailey, M ;
Ebeling, PR ;
Wilson, JW .
EUROPEAN RESPIRATORY JOURNAL, 2005, 25 (01) :54-61
[60]   What is cystic fibrosis? [J].
Knowles, MR ;
Durie, PR .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :439-442